CA2482345A1 - Compounds and compositions for the treatment of diabetes and diabetes-related disorders - Google Patents

Compounds and compositions for the treatment of diabetes and diabetes-related disorders Download PDF

Info

Publication number
CA2482345A1
CA2482345A1 CA002482345A CA2482345A CA2482345A1 CA 2482345 A1 CA2482345 A1 CA 2482345A1 CA 002482345 A CA002482345 A CA 002482345A CA 2482345 A CA2482345 A CA 2482345A CA 2482345 A1 CA2482345 A1 CA 2482345A1
Authority
CA
Canada
Prior art keywords
carbon atoms
group
alkyl
phenyl
haloalkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002482345A
Other languages
English (en)
French (fr)
Inventor
Yamin Wang
Eric S. Mull
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bayer Pharmaceuticals Corp
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2482345A1 publication Critical patent/CA2482345A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CA002482345A 2002-05-31 2003-05-30 Compounds and compositions for the treatment of diabetes and diabetes-related disorders Abandoned CA2482345A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US38459502P 2002-05-31 2002-05-31
US60/384,595 2002-05-31
PCT/US2003/017193 WO2003101988A2 (en) 2002-05-31 2003-05-30 Compounds and compositions for the treatment of diabetes and diabetes-related disorders

Publications (1)

Publication Number Publication Date
CA2482345A1 true CA2482345A1 (en) 2003-12-11

Family

ID=29712061

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002482345A Abandoned CA2482345A1 (en) 2002-05-31 2003-05-30 Compounds and compositions for the treatment of diabetes and diabetes-related disorders

Country Status (7)

Country Link
EP (1) EP1513840B1 (https=)
JP (1) JP2005529160A (https=)
AU (1) AU2003273192A1 (https=)
CA (1) CA2482345A1 (https=)
DE (1) DE60308862T2 (https=)
ES (1) ES2274268T3 (https=)
WO (1) WO2003101988A2 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2007004781A (es) * 2004-10-20 2007-05-11 Applied Research Systems Derivados de 3-arilamino piridina.
WO2013178320A1 (en) * 2012-05-30 2013-12-05 Merck Patent Gmbh Solid state forms of n-((s)-2,3-dihydroxy-propyl)-3-(2-fluoro-4-iodo-phenylamino)-isonicotinamide
JOP20190086A1 (ar) 2016-10-21 2019-04-18 Novartis Ag مشتقات نافثيريدينون جديدة واستخدامها في معالجة عدم انتظام ضربات القلب

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1022214A (en) * 1963-01-31 1966-03-09 Sterling Drug Inc Novel 1,3-disubstituted-1,4-dihydro-4-oxo-1,7-naphthyridines and their preparation
JP3242792B2 (ja) * 1994-08-05 2001-12-25 日本臓器製薬株式会社 ナフチリジニウム誘導体
KR100567649B1 (ko) * 1996-09-25 2006-04-05 아스트라제네카 유케이 리미티드 혈관 내피 성장 인자와 같은 성장 인자의 효과를 억제하는 퀴놀린 유도체

Also Published As

Publication number Publication date
ES2274268T3 (es) 2007-05-16
WO2003101988A2 (en) 2003-12-11
DE60308862D1 (de) 2006-11-16
AU2003273192A8 (en) 2003-12-19
WO2003101988A3 (en) 2004-04-15
DE60308862T2 (de) 2007-04-19
EP1513840A2 (en) 2005-03-16
AU2003273192A1 (en) 2003-12-19
JP2005529160A (ja) 2005-09-29
EP1513840B1 (en) 2006-10-04

Similar Documents

Publication Publication Date Title
JP7772778B2 (ja) 縮合環を有するｇｌｐ－１受容体作動薬を含有する医薬組成物
JP7224086B2 (ja) Ｍｇａｔ２阻害活性を有する縮合環誘導体
JP2018526405A (ja) ［｛［２，３−ジヒドロ−１Ｈ−インデン−１−イル］アミノ｝−２Ｈ，３Ｈ−フロ［３，２−ｂ］ピリジン−３−イル］酢酸、それらの医薬組成物および使用
JP2002105085A (ja) 新規イミダゾチアゾール誘導体
MX2015006591A (es) Nuevos acidos indaniloxi dihidrobenzofuranil aceticos.
WO2021219078A1 (zh) 基于杂环和戊二酰亚胺骨架的化合物及其应用
US20040157904A1 (en) Anilinopyrazole derivatives useful for the treatment of diabetes
WO2005091857A2 (en) 1,6-naphthyridine and 1,8-naphthyridine derivatives and their use to treat diabetes and related disorders
AU2016235263A1 (en) Methods of treating liver disease using indane acetic acid derivatives
JP2012526136A (ja) 抗糖尿病化合物として有用な置換スピロ環式アミン
CN113227093A (zh) 结晶螺环化合物、包含该化合物的剂型、用于疾病治疗的方法和再结晶方法
KR102262275B1 (ko) 헤지호그 경로 길항제 활성을 갖는 키랄 헤테로사이클릭 화합물, 이의 방법 및 용도
WO2004087880A2 (en) Compounds and their use to treat diabetes and related disorders
AU2017223706A1 (en) Combination therapies for treatment of spinal muscular atrophy
JP2020111571A (ja) Ｍｇａｔ２阻害活性を有する縮合環誘導体を含有する医薬組成物
JP2021512112A (ja) グレリンｏ−アシルトランスフェラーゼ（ｇｏａｔ）阻害薬として使用するためのヘテロシクリル置換オキサジアゾロピリジン誘導体
TW201305152A (zh) 具有血管內皮脂肪酶抑制活性之苯并噻唑及吖苯并噻唑衍生物
TWI840489B (zh) 酮衍生物
EP1513840B1 (en) Compounds and compositions for the treatment of diabetes and diabetes-related disorders
KR101705390B1 (ko) 이중환 구조를 갖는 신규한 ｇｐｃｒ 효능제
US20060094714A1 (en) Compounds and their use to treat diabetes and related disorders
US20060009483A1 (en) Compounds and compositions for the treatment of diabetes and diabetes-related disorders
EP1750698A2 (en) 5-anilino-4-heteroarylpyrazole derivatives useful for the treatment of diabetes
WO2005018567A2 (en) Compounds and compositions for the treatment of diabetes and diabetes-related disorders
TW201326158A (zh) 作為ｇｐｒ１１９調節劑之經哌啶基取代的尿素

Legal Events

Date Code Title Description
FZDE Dead